FDA Removes BPC-157, TB-500 and 10 More Peptides from Category 2 (April 2026)

What changed on April 22, 2026: 12 peptides are no longer designated by the FDA as raising "significant safety concerns"^[1].

What did not change: None of these peptides are FDA-approved. None are yet legally authorized for compounding. And none of this has any direct bearing on grey-market research-grade vials that hobbyist researchers buy online. That market operates outside the 503A framework entirely.

What happens next: The PCAC meets July 23–24, 2026 to vote on whether seven of the 12 (BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, Epitalon) should be added to the 503A bulks list. Five more (GHK-Cu injectable, Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, Melanotan II) will be reviewed at a separate PCAC meeting before the end of February 2027^[2][4].

Even if PCAC recommends inclusion, formal FDA rulemaking is still required. That process historically takes over a year^[4].

The 503A bulks list is an FDA framework that governs which bulk drug substances, raw active pharmaceutical ingredients, or APIs, state-licensed compounding pharmacies can legally use to compound medications. Substances on the list fall into one of three interim categories while the FDA evaluates them^[5].

• Category 1: Under evaluation. The FDA does not plan to take enforcement action against pharmacies compounding with these while the review is ongoing.
• Category 2: Raises significant safety concerns. Effectively blocks compounding.
• Category 3: Nominated without adequate scientific support.

In September 2023, the FDA moved roughly 17 peptides into Category 2, which effectively shut down US compounding pharmacy production of these compounds overnight. BPC-157, TB-500, CJC-1295, Ipamorelin, and others disappeared from licensed clinical supply chains within weeks^[6].

On April 15, 2026, the FDA's published notice confirmed that nominators had withdrawn their nominations for 12 peptides, which triggers removal from the category in seven calendar days. I pulled the FDA's updated 503A categories document directly to verify the list^[1]. The full set:

There's a separate, less-reported wrinkle on GHK-Cu: the non-injectable form was also removed from Category 1 (not Category 2) on the same date, because those nominations were also withdrawn^[1]. GHK-Cu is the only compound in this action that appears on both sides of the 503A ledger, and the topical versus injectable distinction matters. The two forms are now on different regulatory tracks.

Removing a substance from Category 2 "because the nominations were withdrawn" sounds bureaucratic, but it's the procedural lever that was used here. Under the FDA's interim policy, once a nomination is withdrawn, the agency must remove the substance from the category after seven days^[5]. The FDA then has to decide whether to put it back through the bulks list review from scratch, which is exactly what's happening at PCAC on July 23–24.

Secretary Kennedy directed the FDA to review the Category 2 list after his February 27 remarks on Joe Rogan, and industry observers including Hyman, Phelps & McNamara and Polsinelli have described the April 15 action as a coordinated response driven by that political pressure^[3][4][7][9]. The FDA's own docket notice confirms that the PCAC review is specifically tied to whether these peptides should be included on the 503A bulks list for use in compounding^[8].

Several outlets framed the April 15 action as a "reinstatement" of these peptides, or suggested that compounding pharmacies could now legally produce them again starting April 22. That's wrong, and the legal analyses I reviewed make this point explicitly.

From the Orrick analysis published April 16: removal from Category 2 does not, by itself, place these substances on the 503A bulks list or into Category 1 for which FDA is exercising enforcement discretion. The peptides remain in a regulatory gray area until the PCAC meets and the FDA takes final action^[7].

Polsinelli's writeup reached the same conclusion: procedural removal should not be read as a go-ahead to compound these peptides. Under FDA's current policy, removal of a bulk drug substance from Category 2 does not, on its own, authorize use of that substance in compounding or bring it within FDA's interim enforcement discretion policy for substances in Category 1^[4].

I reviewed the FDA's own notice language against both of these readings and they track^[1]. The operative sentence is simply that the substance "will be removed from category 2." It does not say that compounding is now permitted. It says the safety-concern designation is lifted, pending PCAC review.

For compounding pharmacies, the practical read is: exercise caution until the FDA takes final action.

For the hobbyist research community, the practical read is: this changes almost nothing. Grey-market research-grade vials were never flowing through the 503A compounding pathway in the first place. They're sold as research use only products, outside the compounding framework entirely. The April 15 action doesn't clean up that market, regulate it, or make it riskier. It simply doesn't touch it.

Here's the per-compound breakdown of what changed on April 22 and what comes next. Where PepPal or PDP already has a protocol page for the peptide, I've linked it. the dosing, reconstitution, and trial data on those pages are unchanged by this regulatory action.

None of this action regulates or changes the grey-market research-grade peptide supply chain. Suppliers like Peptide Partners and Orbitrex sell research-grade vials labeled for research use only, a separate legal and commercial track from the 503A compounding pathway the FDA is evaluating.

If PCAC votes favorably in July 2026:Compounding pharmacies will have a formal pathway to produce BPC-157, TB-500, KPV, MOTs-C, DSIP, Semax, and Epitalon under physician prescription, after FDA rulemaking concludes. That's likely a 2027 event at the earliest given how bulks list rulemaking has moved historically^[4]. Compounded peptides would flow through prescription, not direct-to-consumer sales.

For quality-conscious researchers: The more relevant question is still supplier testing quality, which is what the Finnrick grading system tracks. I've reviewed independent test data for Peptide Partners and Orbitrex across multiple peptides this quarter, and both have consistent third-party COA coverage on the compounds affected by this action. None of that changes on April 22. If you want to verify COA quality yourself, I wrote a full guide to reading peptide COAs.

For pricing: If compounded peptides become legally available through pharmacies in 2027, expect per-vial pricing to be substantially higher than current research-grade pricing. Compounded pharmacy products carry pharmacy margins, physician consult costs, and sterile preparation fees. The grey-market research channel has historically undercut compounded pricing by 5–10x on the same peptide, and that spread is unlikely to close.

If you want to weigh in directly on the PCAC review, the FDA has established a public docket:

• Docket number: FDA-2026-N-2979^[8]
• Comments received by July 9, 2026 will be provided directly to the Committee before the July 23–24 meeting.
• Comments received by July 22, 2026 will still be considered by FDA but may not reach the Committee members before the vote.
• Oral presentation requests at the meeting must be submitted by June 30, 2026.
• The meeting will be held at FDA's White Oak Campus in Silver Spring, MD, with a live webcast.

Comments can be submitted at regulations.gov. This is the most substantive public input opportunity on peptide compounding since the 2023 Category 2 designation, so if you have scientific, clinical, or operational data relevant to any of the seven peptides up for review, it's worth putting it on the record.

April 22, 2026 removed a regulatory label. It did not open a market, authorize compounding, or change the grey-market research supply chain.

The actual inflection point is the July 23–24 PCAC meeting. That's where BPC-157, TB-500, KPV, MOTs-C, DSIP, Semax, and Epitalon either get a formal recommendation toward 503A inclusion, which would eventually unlock compounded-pharmacy access under physician prescription, or they don't, and they return to the regulatory gray area indefinitely.

Five more peptides (GHK-Cu injectable, Melanotan II, LL-37, Dihexa, PEG-MGF) are in the same gray area but on a slower PCAC track that doesn't resolve until early 2027 at the earliest.

My editorial take, for what it's worth: this is the most favorable peptide regulatory news since 2023, but the framing in a lot of the headlines is ahead of the legal reality. I'll update this post as PCAC agendas and votes land. For the underlying science, dosing, and reconstitution math on each of the 12 compounds, the protocol pages linked throughout this piece are the reference. For the broader regulatory context, my earlier March 2 fact-check of the Joe Rogan comments is still the right background reading. It's no longer current on the April 15 action, but the underlying framework it walks through (503A, PCAC, bulks list, Category 1 vs. 2 vs. 3) is exactly what I've summarized above.

If you're planning to run a peptide that's affected by this action and want to make sure your reconstitution math is correct for whatever vial size you have, the free PepPal calculator handles that.